Infigratinib - Helsinn/QED Therapeutics
At a glance
- Drug Originator Novartis
- Drug Licenced by Helsinn; Juniper Biologics; Kyowa Kirin; QED Therapeutics; Xediton Pharmaceuticals
- Drug Class Aniline compounds; Antineoplastics; Chlorobenzenes; Methylurea compounds; Phenyl ethers; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
- USA Patent Applicants HELSINN HLTHCARE
- USA Patents 4
- NDAs 1
- International Patents 135
- Patent Applications 24

Disclaimer